Poolbeg has announced positive Phase Ib data with POLB 001 in the LPS challenge study, a surrogate for acute influenza infection. The positive data validates the POLB 001 mechanism of action as an acute anti-inflammatory approach, de-risks the programme and increases the likelihood that it could be partnered and generate a good return on investment for shareholders. We increase our risk-adjusted DCF target price from 15p to 19p; there are no changes to forecasts.
02 Mar 2023
Poolbeg Pharma - Positive POLB 001 data read-out
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Poolbeg Pharma - Positive POLB 001 data read-out
Poolbeg Pharma PLC (POLB:LON) | 14.0 0 0.0% | Mkt Cap: 70.2m
- Published:
02 Mar 2023 -
Author:
Mark Brewer | Cavendish Research -
Pages:
11
Poolbeg has announced positive Phase Ib data with POLB 001 in the LPS challenge study, a surrogate for acute influenza infection. The positive data validates the POLB 001 mechanism of action as an acute anti-inflammatory approach, de-risks the programme and increases the likelihood that it could be partnered and generate a good return on investment for shareholders. We increase our risk-adjusted DCF target price from 15p to 19p; there are no changes to forecasts.